Small molecules shed light on cancer therapies

August 23, 2011

Patients suffering from an aggressive brain cancer will benefit from the results of a University of Illinois study that could advance the development of targeted gene therapies and improve prognosis.

"We have advanced the understanding of the role of microRNAs on glioblastoma multiforme, a deadly brain cancer, by studying the networks between the microRNAs and their target genes associated with different stages of cancer development and progression," said Kristin Delfino, a U of I doctoral candidate in animal science with a focus in genetics and bioinformatics.

What exactly are microRNAs? microRNAs are small, non-coding RNA molecules that regulate the expression of genes such as oncogenes or tumor suppressor genes. U of I researchers used a novel approach to identify the simultaneous association between tens of thousands of microRNAs, target genes, and glioblastoma progression and survival.

Delfino integrated clinical information such as race, gender, therapy, survival, and cancer stage from 253 patients together with genome-wide microRNA and gene expression data.

"We looked at the big picture and how microRNAs work together," Delfino said. "When you look at a single microRNA alone, it can seem significant. But when you evaluate it in the context of all other microRNAs, some turn out to be more significant and others may not be as significant as they appear on their own. The systems biology approach that we implemented is critical for understanding the gene pathways influencing cancer."

The study evaluated 534 microRNAs together, unlike the typical method of studying one at a time. They confirmed 25 microRNAs previously associated with glioblastoma survival and identified 20 other microRNAs associated with initiation or growth of other cancer types such as breast cancer, ovarian cancer and gastric adenocarcinoma.

"These findings suggest common pathways that can be targeted with similar drugs already developed and tested for other cancers," said Sandra Rodriguez Zas, co-researcher and U of I professor of animal science and bioinformatics.

In addition, researchers found that some of the microRNA biomarkers of survival are personalized, Rodriguez Zas said. This means that they are particularly useful for patients of a specific race, gender or therapy. Other microRNAs are equally effective regardless of the clinical conditions of the patient.

"These biomarkers can serve as the basis to dig deeper into cancer studies," Delfino said. "Cancer affects us all in one way or another. Unfortunately, we still don't know how it's caused, what takes place when it is caused and how to cure it. But these biomarkers give us guidance into developing specific gene therapies to target glioblastoma."

Today patients can easily and cheaply be screened for microRNA and target gene levels, Rodriguez Zas said.

"Based on our research, that information can be used to select the most effective therapy and develop prognosis strategies," Rodriguez-Zas said.

###

This study, "Therapy-, Gender- and Race-specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival," was published in Cancer Genomics & Proteomics. Co-researchers include Kristin Delfino, Nicola Serao, Bruce Southey and Sandra Rodriguez Zas, all of the U of I.

University of Illinois College of Agricultural, Consumer and Environmental Sciences

---

---

	Medifocus Guidebook on: Glioblastoma by Medifocus.com Inc. (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Glioblastoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Glioblastoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Glioblastoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations...
	Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever.  A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor.  I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor.  This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years.  I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level.  I could not find, so I wrote one.  I maintained a detailed journal.  I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second...
	Glioblastoma Multiforme by James Markert (Author), Vincent T. DeVita Jr. (Author), Steven A. Rosenberg (Author), Samuel Hellman (Author) This Book Provides Basic Researchers And Clinicians With A Contemporary Review Of The Epidemiology, Diagnosis, And Treatment Of Glioblastoma Multiforme, The Most Common And Most Deadly Type Of Brain Tumor. Expert Malignant Glioma Researchers And Clinicians Provide State-Of-The-Art Chapters On Important Topics Such As Molecular Genetic Classification Of Glioblastoma, Surgical Management, Stem Cell Therapy, Chemotherapy, Angiogenesis, And More.
	Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About by Ben A. Williams (Author) Describes how to use the Internet and other sources to learn about experimental drug trials, effective forms of alternative medicine, and other breakthroughs with the potential for dramatically improving the odds of successful treatment.
	What You Need to Know About Glioblastoma Cancer - It's Your Life, Live It! by Cancer Group Institute As an Oncology Nurse. I had only one protocol in mind while writing this 195 page book. That was to show you the most successful cancer treatments available today for Glioblastoma Cancer. To that end, you won't find a better warrior in the war on cancer than reading this book. We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional Cancer Center, Instituto Oncologia Moderna, Puerto Rico plus many others. It is critical to get prompt diagnosis and proper treatment for glioblastoma cancer, this can literally make the difference between life and death. Understanding your options will give you...
	Glioblastoma:: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies by Swapan K. Ray (Editor) Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for...
	Tumors of the Central Nervous System, Volume 1: Gliomas: Glioblastoma (Part 1) by M. A. Hayat (Editor) The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers is included. The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of cancer stem cells in the initiation, progression, and persistence of malignant gliomas is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed.
	Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional...
	Tumors of the Central Nervous System, Volume 2: Gliomas: Glioblastoma (Part 2) by M.A. Hayat (Editor) Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients...
	A Statistic of One: My Walk With Glioblastoma Multiforme by Stephen Hatrak (Author) A Statistic of One: My Walk with Glioblastoma Multiforme traces Stephen Hatrak's life from his diagnosis of glioblastoma multiforme, the deadliest of malignant brain tumors, to the present. He chronicles the trials and tribulations he faced and the losses he suffered along his journey. Faith and inner strength are formidable allies in overcoming any tragedy in one's life, and they played vital roles in his struggle. He was told from the start that the he might have twelve months to live; even so, he defi ed the odds and, six years later, is telling his own story. Despite the dire statistics associated with a diagnosis of glioblastoma, there are several stories of long-term survival; these stories gave him hope that this cancer could be tamed. To overcome this challenge in his life, he had...